TG Therapeutics concludes enrolment in Phase III Briumvi trial [Yahoo! Finance]
TG Therapeutics, Inc. (TGTX)
Last tg therapeutics, inc. earnings: 11/12 07:34 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.tgtherapeutics.com
Company Research
Source: Yahoo! Finance
Currently approved in the US and selected regions outside the US, Briumvi is now given as a one-hour intravenous (IV) infusion biannually following the initial dose. The randomised, non-inferiority, parallel-group, multi-centre, open-label trial will compare the pharmacodynamics, pharmacokinetics, radiological, safety, and clinical outcomes of subcutaneous Briumvi with IV Briumvi among adults with RMS. Participants have been randomly assigned to receive either an every eight-week regimen or an every 12-week regimen of subcutaneous Briumvi, or the approved IV dosing schedule. The trial's primary endpoint is to demonstrate non-inferior drug exposure for subcutaneous Briumvi compared to IV administration, measured as area under the curve (AUC) at week 24. Briumvi is a monoclonal antibody that targets a specific epitope on cluster of differentiation 20 (CD20)-expressing B-cells. It is approved in the US for adults with RMS, and in the European Union and the UK for adults with a
Show less
Read more
Impact Snapshot
Event Time:
TGTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TGTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TGTX alerts
High impacting TG Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TGTX
News
- TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI [Yahoo! Finance]Yahoo! Finance
- TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVIGlobeNewswire
- TG Therapeutics: Briumvi Performance Aiding Upside, Buybacks Limiting Downside [Seeking Alpha]Seeking Alpha
- A Look At TG Therapeutics (TGTX) Valuation After New US$750 Million Credit Facility [Yahoo! Finance]Yahoo! Finance
- TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 MillionGlobeNewswire
TGTX
Earnings
- 2/26/26 - Miss
TGTX
Analyst Actions
- 2/2/26 - JP Morgan
TGTX
Sec Filings
- 3/27/26 - Form SCHEDULE
- 3/20/26 - Form 8-K
- 2/27/26 - Form 10-K
- TGTX's page on the SEC website